{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:14:02Z","timestamp":1780352042232,"version":"3.54.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Prolactinomas (PRLs) are prevalent pituitary adenomas associated with metabolic changes and increased cardiovascular morbidity. This study examined clinical, endocrine, metabolic, and inflammatory profiles in PRL patients, aiming to identify potential prognostic markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study comprised data from 59 PRL patients gathered in a registry at the University Hospital of Zurich. Diagnostic criteria included MRI findings and elevated serum prolactin levels. We assessed baseline and follow-up clinical demographics, metabolic markers, serum inflammation-based scores, and endocrine parameters. Treatment outcomes were evaluated based on prolactin normalization, tumor shrinkage, and cabergoline dosage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The PRL cohort exhibited a higher prevalence of overweight\/obesity, prediabetes\/diabetes mellitus, and dyslipidemia compared to the general population. Significant correlations were found between PRL characteristics and BMI, HbA1c, and fT4 levels. Follow-up data indicated decreases in tumor size, tumor volume, prolactin levels, and LDL-cholesterol, alongside increases in fT4 and sex hormones levels. No significant associations were observed between baseline parameters and tumor shrinkage at follow-up. A positive association was noted between PRL size\/volume and the time to achieve prolactin normalization, and a negative association with baseline fT4 levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study underscores the metabolic significance of PRL, with notable correlations between PRL parameters and metabolic indices. However, inflammatory markers were not significantly correlated with patient stratification or outcome prediction. These findings highlight the necessity for standardized follow-up protocols and further research into the metabolic pathogenesis in PRL patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1363939","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:53:30Z","timestamp":1712292810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolic and inflammatory parameters in relation to baseline characterization and treatment outcome in patients with prolactinoma: insights from a retrospective cohort study at a single tertiary center"],"prefix":"10.3389","volume":"15","author":[{"given":"Susanna","family":"Hofbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Horka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Seidenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Da Mutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Regli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Erlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2017.01.004","article-title":"Genetic aspects of pituitary adenomas","volume":"46","author":"Marques","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.01.004","article-title":"Time for a new perspective on prolactin in metabolism","volume":"31","author":"Macotela","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199405000-00007","article-title":"Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels","volume":"34","author":"Smith","year":"1994","journal-title":"Neurosurgery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02744-8","article-title":"Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas","volume":"74","author":"Wright","year":"2021","journal-title":"Endocrine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-021-02744-8","article-title":"Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size","volume":"133","author":"Burke","year":"2019","journal-title":"J Neurosurg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice","volume":"362","author":"Klibanski","year":"2010","journal-title":"Prolactinomas N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs233","article-title":"Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality","volume":"35","author":"Haring","year":"2014","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345182","article-title":"Insulin sensitivity and hyperprolactinemia","volume":"26","author":"Tuzcu","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF00745135","article-title":"Prolactin: a diabetogenic hormone","volume":"13","author":"Landgraf","year":"1977","journal-title":"Diabetologia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03397.x","article-title":"Hyperinsulinaemia in hyperprolactinaemic women","volume":"13","author":"Johnston","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)49291-5","article-title":"Decreased sensitivity to insulin in women with microprolactinomas","volume":"45","author":"Serri","year":"1986","journal-title":"Fertil Steril"},{"key":"B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","article-title":"Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline","volume":"7","author":"Pala","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","article-title":"Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy","volume":"14","author":"Berinder","year":"2011","journal-title":"Pituitary"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine","volume":"147","author":"Doknic","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.2.7979","article-title":"Body weight and fat deposition in prolactin receptor-deficient mice","volume":"142","author":"Freemark","year":"2001","journal-title":"Endocrinology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.02.005","article-title":"Focus on prolactin as a metabolic hormone","volume":"17","author":"Ben-Jonathan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"B19","article-title":"The effect of endocrine disorders on lipids and lipoproteins","volume-title":"Endotext [Internet]","author":"Feingold","year":"2000"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1002320","article-title":"Metabolic effects of prolactin and the role of dopamine agonists: A review","volume":"13","author":"Kirsch","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","article-title":"The effects of hyperprolactinemia and its control on metabolic diseases","volume":"13","author":"Auriemma","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11060-010-0459-3","article-title":"Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist","volume":"104","author":"Yang","year":"2011","journal-title":"J Neurooncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12902-021-00889-1","article-title":"The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis","volume":"21","author":"Zou","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab074","article-title":"Cure and hormonal control after prolactinoma resection: case series and systematic review","volume":"5","author":"Penn","year":"2021","journal-title":"J Endocr Soc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab238","article-title":"Serum inflammation-based scores in endocrine tumors","volume":"106","author":"Marques","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01112-5","article-title":"Pre-operative serum inflammation-based scores in patients with pituitary adenomas","volume":"24","author":"Marques","year":"2021","journal-title":"Pituitary"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0589","article-title":"Metabolic impact of pheochromocytoma\/paraganglioma: targeted metabolomics in patients before and after tumor removal","volume":"181","author":"Erlic","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa954","article-title":"Targeted metabolomics as a tool in discriminating endocrine from primary hypertension","volume":"106","author":"Erlic","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0109","article-title":"Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome","volume":"177","author":"Di Dalmazi","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1055\/a-0649-0960","article-title":"Metabolic alterations in patients with pheochromocytoma","volume":"127","author":"Erlic","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabet.2019.02.003","article-title":"Links between aldosterone excess and metabolic complications: A comprehensive review","volume":"46","author":"Bothou","year":"2020","journal-title":"Diabetes Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/142425","article-title":"Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients","volume":"2014","author":"Bugada","year":"2014","journal-title":"BioMed Res Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00886","article-title":"Preoperative changes in hematological markers and predictors of glioma grade and survival","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142159","article-title":"The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers","volume":"10","author":"Watt","year":"2015","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"2015","author":"Lacroix","year":"9996","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0889-8529(18)30204-4","article-title":"Clinical manifestations of acromegaly","volume":"21","author":"Molitch","year":"1992","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.04.004","article-title":"The immune system in Cushing's syndrome","volume":"31","author":"Hasenmajer","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09560-x","article-title":"Acromegaly, inflammation and cardiovascular disease: a review","volume":"21","author":"Wolters","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03752.x","article-title":"Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma","volume":"73","author":"Erem","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105397","article-title":"The prognostic role of preoperative systemic immune-inflammation index and albumin\/globulin ratio in patients with newly diagnosed high-grade glioma","volume":"184","author":"Liang","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.181.2.1810577","article-title":"MR imaging features of thyrotropin-secreting pituitary adenomas at initial presentation","volume":"181","author":"Sarlis","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"B45","unstructured":"Herz- und Kreislauferkrankungen2023"},{"key":"B46","unstructured":"Diabetes2023"},{"key":"B47","unstructured":"\u00dcbergewicht2023"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2006.10955","article-title":"Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma","volume":"136","author":"Schmid","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345636","article-title":"Body fat in men with prolactinoma","volume":"31","author":"Naliato","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.09.001","article-title":"Association between prolactinoma and body mass index","volume":"27","author":"Al Sabie","year":"2021","journal-title":"Endocr Pract"},{"key":"B51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-021-00733-6","article-title":"Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study","volume":"21","author":"Posawetz","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100258","article-title":"Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term","volume":"24","author":"Andereggen","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1015520","article-title":"Metabolic effects of prolactin","volume":"13","author":"Pirchio","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01534.x","article-title":"Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults","volume":"14","author":"Gibson","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S397445","article-title":"Effects of anterior pituitary adenomas' Hormones on glucose metabolism and its clinical implications","volume":"16","author":"Li","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00671.x","article-title":"Adipocyte prolactin: regulation of release and putative functions","volume":"9","author":"Brandebourg","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00345","article-title":"Metabolic disorders and male hypogonadotropic hypogonadism","volume":"10","author":"Pivonello","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-016-9882-2","article-title":"Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas","volume":"32","author":"Schwetz","year":"2017","journal-title":"Metab Brain Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","article-title":"Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas","volume":"101","author":"Auriemma","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.2.6346","article-title":"Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors","volume":"85","author":"Bulow","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002097","article-title":"Hypopituitarism and atherosclerosis","volume":"33","author":"Elhadd","year":"2001","journal-title":"Ann Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12124","article-title":"Does hypopituitarism recover when macroprolactinomas are treated with cabergoline","volume":"79","author":"Karavitaki","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.5.6611","article-title":"The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas","volume":"85","author":"Arafah","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.05.249","article-title":"Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure","volume":"129","author":"Akinduro","year":"2019","journal-title":"World Neurosurg"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1363939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:53:34Z","timestamp":1712292814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1363939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":65,"alternative-id":["10.3389\/fendo.2024.1363939"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1363939","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"article-number":"1363939"}}